Indivior (INDV) director David Wheadon awarded 5,955 RSUs, now holds 20,350 shares

Rhea-AI Filing Summary

Indivior Pharmaceuticals director David E. Wheadon reported a grant of 5,955 shares of common stock on January 26, 2026, reflected as an acquisition at a price of $0 per share. After this equity grant, he beneficially owned 20,350 shares in total.

The grant consists of restricted stock units (RSUs), each representing a right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholder meeting following the grant date, contingent on his continued service to Indivior through that vesting date.

Insights

Equity compensation and governance analyst

Routine RSU grant to an Indivior director with service-based vesting.

The filing shows David E. Wheadon, a director of Indivior Pharmaceuticals, Inc., receiving 5,955 restricted stock units on January 26, 2026 at $0 per share. After this grant he holds 20,350 common shares directly.

The RSUs convert into common stock on a service-based schedule. Vesting occurs immediately before the first annual stockholder meeting following the grant date, assuming he continues serving as a director. This aligns equity incentives with ongoing board service and the company’s annual governance cycle.

The transaction appears as standard director compensation rather than a discretionary market purchase or sale. Actual impact for shareholders depends on future vesting and settlement of the RSUs, as well as any subsequent transactions reported in later periods.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wheadon David E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,955	$0.00	--

Holdings After Transaction: Common Stock — 20,350 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wheadon David E.

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		5,955(1)	A	$0	20,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Remarks:

	/s/ Jordan Saltzberg, Power of Attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Indivior (INDV) report for David E. Wheadon?

Indivior reported that director David E. Wheadon received an equity grant of 5,955 restricted stock units on January 26, 2026. The grant was recorded at $0 per share and increased his beneficial ownership to 20,350 common shares.

How many Indivior (INDV) shares does director David E. Wheadon now beneficially own?

After the reported grant, director David E. Wheadon beneficially owns 20,350 shares of Indivior common stock. This total includes the 5,955 restricted stock units granted on January 26, 2026, which each represent a right to receive one share upon vesting.

What are the terms of the restricted stock units granted to Indivior (INDV) director David E. Wheadon?

The filing states the grant consists of restricted stock units (RSUs), each equal to one share of common stock. These RSUs vest immediately before the first annual stockholder meeting following the grant date, subject to Wheadon’s continued service to Indivior through that vesting date.

Was there any cash paid in the Indivior (INDV) RSU grant to David E. Wheadon?

No cash changed hands in the reported grant. The transaction code shows an acquisition of 5,955 shares at a stated price of $0 per share. This reflects equity compensation rather than an open-market purchase of Indivior stock.

Is the Indivior (INDV) RSU grant to David E. Wheadon a purchase or a compensation award?

The transaction is a compensation award, not a market purchase. It is described as a grant of restricted stock units at $0 per share, contingent on continued service and vesting before the first annual meeting after the grant date.

How do the RSUs granted to Indivior (INDV) director David E. Wheadon convert into shares?

Each RSU granted to David E. Wheadon represents a contingent right to receive one share of Indivior common stock. The RSUs vest on the day immediately preceding the first annual stockholder meeting after the grant date, provided he remains in service until that date.